AstraZeneca hits snag in coronavirus drug development

accreditation
Vials of AstraZeneca vaccines.
Vials of AstraZeneca vaccines.
Beckmann/BSR Agency/Getty Images
  • AstraZeneca says it has hit a snag in developing treatments for Covid-19.
  • Its vaccine, developed along with Oxford University, is still experiencing doubt over its safety.
  • The treatment made, has failed its main goal to treat Covid-19 in exposed patients.

Covid-19 vaccine maker AstraZeneca on Tuesday revealed it had hit a setback in trials of a treatment for the Covid-19.

The drug, made from a combination of two antibodies, failed its main goal to treat Covid-19 symptoms in exposed patients, AstraZeneca said in a statement.

The treatment has been undergoing phase 3 or final clinical trials to assess its safety and efficacy.

AstraZeneca said that 1 121 unvaccinated adults had been exposed to an infected person as part of the trial.

Treatment AZD7442 reduced the risk of developing symptoms by only 33% - which was "not statistically significant", it added.

The company is nevertheless continuing trials to assess whether the drug can prevent Covid or treat more severe symptoms.

WATCH | 101-year-old gets vaccine after surviving Covid-19

The US government has funded the development of AZD7442 and has agreements to receive 700 000 doses.

Meanwhile, AstraZeneca's Covid-19 vaccine, which was developed with the University of Oxford, continues to face safety doubts.

The jab has been suspended in several European countries over reports of rare blood clots.

A top official in the European Medicines Agency on Sunday suggested that it might be worth abandoning AstraZeneca's coronavirus vaccine for all age groups where alternatives are available.

However, a study from British health authorities showed on Monday that two doses of AstraZeneca/Oxford or rival Pfizer/BioNTech vaccines stopped the need for in-patient treatment in more than 90 percent of cases of the Delta variant.

The UK government on Monday announced a four-week delay to the full lifting of coronavirus restrictions in England due to a surge in infections caused by Delta, which first appeared in India.

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Lockdown For
DAYS
HRS
MINS
Voting Booth
Please select an option Oops! Something went wrong, please try again later.
Results
Yes, I believed it was authentic
7% - 146 votes
Yes, I didn't want to spend that much money on the original item
20% - 440 votes
No, I always shop at reputable stores
15% - 312 votes
No, I don't wear designer clothing
58% - 1253 votes
Vote
Rand - Dollar
14.80
-0.3%
Rand - Pound
20.31
-0.3%
Rand - Euro
17.37
-0.2%
Rand - Aus dollar
10.80
-0.3%
Rand - Yen
0.13
-0.1%
Gold
1,755.78
+0.8%
Silver
22.74
+1.0%
Palladium
2,015.00
+1.4%
Platinum
989.50
-0.3%
Brent Crude
77.25
+1.4%
Top 40
57,643
0.0%
All Share
64,049
0.0%
Resource 10
57,254
0.0%
Industrial 25
82,879
0.0%
Financial 15
14,316
0.0%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE